Clear visual breakdown: for every ₹100 earned, see how much flows to salaries, operating costs, government taxes, EPS profit, and your share.
Profit Conversion
₹6.0/ ₹100
Moderate volume margin
Human Capital & Talent
₹12.0/ ₹100
Workforce salaries, engineers & talent
Earnings Per Share (EPS)
₹16.67/ share
Annual profit generated per stock unit
Shareholder Payout
₹2.4/ ₹100
Direct cash dividends & buybacks
Multi-Stage Money Stream (Sankey Flow)
Hover or drag nodes to inspect connections and money volumeMode: Every ₹100 Company Sales
Revenue
Materials / Production
Human Capital (Talent)
Government Taxes
Net Profit / EPS
Dividends & Reinvestment
Topline Money Inflow100.0%
Gross Commercial Revenue
₹100.00per ₹100 sales
For every ₹100 collected by AKUMS DRUGS AND PHARMA L from customers and clients globally.
Raw Materials, Energy & Inventory59.9%
Direct Production & Materials (COGS)
₹59.94per ₹100 sales
Direct physical costs required to produce the company's products, chip fabrication, server components, or merchandise.
Salaries, Benefits, R&D & Talent12.0%
Human Capital & Engineering Workforce
₹12.00per ₹100 sales
Compensation paid to software engineers, technicians, designers, operators, and staff driving the business forward.
Cloud Servers, Sales, Marketing & Legal27.7%
Operating, Tech & Administrative (SG&A)
₹27.66per ₹100 sales
Essential business operations including data center infrastructure, global marketing, compliance, and office facilities.
Interest to Bank Lenders & Bondholders2.1%
Debt Servicing & Financing Costs
₹2.08per ₹100 sales
Cost of borrowed capital. Lower interest outlays indicate low debt dependency and strong financial solvency.
Direct Corporate Tax Paid to State3.0%
Government Corporate Taxes
₹2.96per ₹100 sales
Statutory income taxes contributed to national infrastructure, roads, defense, and public governance.
Pure Profit Belongs to Shareholders6.0%
Net Bottom-Line Profit (EPS Engine)
₹6.00per ₹100 sales
The ultimate earnings of the company. This forms your Diluted EPS (₹16.67/share) and belongs entirely to equity owners.
Cash Deposited to Investor Bank Accounts1.5%
Direct Cash Dividends
₹1.50per ₹100 sales
Actual liquid profits credited directly into your brokerage or bank account as passive dividend cash flow.
Reduces Share Count to Elevate EPS0.9%
Share Repurchases (Buybacks)
₹0.90per ₹100 sales
The company buys its own shares off the market and retires them, making your remaining shares represent a larger slice of future profits.
Reinvested in New Factories, AI & Tech5.4%
Capital Expenditure (Growth CapEx)
₹5.42per ₹100 sales
Long-term capital assets purchased: next-gen server clusters, robotics, retail stores, or production assembly lines.
Retained Earnings on Balance Sheet3.6%
Treasury Reserves & War Chest
₹3.60per ₹100 sales
Cash reserves stored in bank deposits, treasuries, and safe liquid investments to withstand crises and fund sudden strategic acquisitions.
Shareholder Capital Simulator: Where Does Your Investment Go?
Select or type any investment amount to see how much commercial activity and earnings your money commands in AKUMS DRUGS AND PHARMA L.
Your Investment:₹50,000 (~68.0 shares at ₹734.95/share)
Annual Revenue
₹18,891
Generated by your capital
Human Capital
₹2,267
Engineers & staff salaries
Taxes Paid
₹559
Public infrastructure
Your Net Earnings
₹1,134
Annual profit earned by you (2.3% yield)
Cash Dividend
₹284
Direct cash to your bank
Growth CapEx
₹1,025
Reinvested in tech & expansion
How to read this flow diagram as an investor:Revenue represents gross sales (₹100). Before any profit can reach you, the company must first pay suppliers (COGS), its workforce & engineers (Human Capital), rent & technology (SG&A), lenders (Interest), and the government (Taxes). What remains is Net Profit (Diluted EPS). Healthy companies divide this profit between Cash Dividends, Share Buybacks (retiring shares to boost your percentage ownership), and CapEx Reinvestment to build new capacity for future years.
Key Fundamentals & Ratios
Real-Time Screener Matrix
Market Cap
₹11,252 Cr
Mid Cap
Current Price
₹734.95
-1.30% today
52W High / Low
₹838.8 / ₹409.3
Past 52 weeks historical
Stock P/E
30.5
Forward: 21.5
Book Value
₹228.76
Price to Book: 3.21x
Dividend Yield
0.14%
Annualised distribution
Return on Equity (ROE)
10.9%
Shareholder returns efficiency
1-Year Return
+64.24%
52W change percent
52W Low: ₹409.30Current price sits at 76% of 52W range52W High: ₹838.80
About AKUMS DRUGS AND PHARMA L
Healthcare & Pharma
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
TTM Revenue₹4,829 Cr
Net Profit Margin7.5%
Operating Margin13.2%
EPS (Trailing)₹24.07
Peer Comparison
Comparing AKUMS DRUGS AND PHARMA L with leading competitors in Healthcare & Pharma (Indian Market)
Data Provenance & Regulatory DisclosureSource: NSE/BSE Statutory Filings
Quotes are delayed by at least 15 minutes. Financial metrics and disclosures are cross-referenced with periodic statutory disclosures from the National Stock Exchange of India (NSE) and BSE India. This content is provided strictly for educational and portfolio analytics purposes, and does not constitute investment advice or Buy/Sell recommendations.
